Document is current
Any future updates will be listed below
-
Authors
Grønbæk, Ida Marie Bruun https://orcid.org/0009-0004-0502-5888
Halkjær, Sofie Ingdam https://orcid.org/0000-0001-7518-4252
Mollerup, Sarah https://orcid.org/0000-0003-2429-4018
Hansen, Esben Holm https://orcid.org/0000-0001-8078-5941
Paulsen, Sarah Juel https://orcid.org/0009-0004-6102-1582
Engel, Sara https://orcid.org/0000-0001-7026-2741
Theede, Klaus https://orcid.org/0000-0003-2692-6840
Wilkens, Rune https://orcid.org/0000-0002-4928-4708
Boysen, Trine https://orcid.org/0000-0002-5116-5716
Petersen, Andreas Munk https://orcid.org/0000-0003-0531-0553
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04842149 at ClinicalTrials.govDocuments that mention this clinical trial
The effects of probiotic treatment with Bifidobacterium breve, Bif195 for small intestinal Crohn’s disease and the gut microbiome: results from a randomised, double-blind, placebo-controlled trial
https://doi.org/10.1186/s13099-025-00692-6
-
Funding
Funding for this research was provided by:
The Capital Region’s Research Foundation for Health Research (A6876)
Copenhagen University
- License Information
-
More Information
Article History
Received: 25 February 2025
Accepted: 20 March 2025
First Online: 9 April 2025
Declarations
:
: The study is approved by the Danish Data Protection Agency (P-2020-1136) and the Scientific Ethics Committee for Copenhagen Regional Hospitals, Denmark (Permission no.: H-20068527). The study was performed in accordance with the Revised Declaration of Helsinki. All participants were given verbal and written information and provided written informed consent to participate in the study. The study is registered at as NCT04842149.
: Not applicable.
: Bifidobacterium breve, Bif195™ is marketed under the name GALENEX™ and is a registered trademark of Chr. Hansen A/S. Author SE is an employee of Chr. Hansen A/S, part of Novonesis.
